Retrospective analysis identifies significant risks of PTLD among pediatric liver transplantation recipients, suggesting urgent prevention needs.
Key Points
This analysis aimed to explore the clinical features and risks of posttransplant lymphoproliferative disorders (PTLD) in pediatric liver transplant recipients.
Conducted a retrospective study on 2032 pediatric liver transplant recipients from 2006 to 2019.
Analyzed incidence and timing of PTLD onset in these recipients.
Used multivariable cox regression to identify risk factors for PTLD.
84 out of 2032 patients (4.13%) were diagnosed with PTLD.
Cumulative incidence reached 5.9% at 5 years and 7.7% at 10 years after transplantation.
Median time to PTLD onset was 15.7 months, with most cases occurring between 3 and 18 months post-LT.
Epstein-Barr virus infection and tacrolimus were significant risk factors for developing PTLD.